Primary care data sharpens the picture of PLE in Pugs

Protein-losing enteropathy in Pugs may be deadlier, and more manageable in primary care, than many clinicians assumed. A new VetCompass-based retrospective study in the Journal of Small Animal Practice reviewed 51 UK Pugs diagnosed with PLE between 2017 and 2024 and found that 43.1% died from the condition, with more than half of those deaths occurring within three months of diagnosis. Among treated dogs, prednisolone and clopidogrel were associated with better short-term survival, while referral to specialist care was not linked to significantly different survival at three months, one year, or two years. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For veterinary professionals, the study adds real-world primary care data to a disease area that has often been shaped by referral-hospital experience. That matters because 58.8% of the Pugs in this dataset were managed without referral, yet their survival outcomes did not differ significantly from referred cases in this retrospective analysis. The findings suggest that early recognition, prompt medical treatment, and close monitoring in first-opinion practice may meaningfully influence outcomes, especially in a breed already shown in prior research to face elevated PLE-related risk, including higher in-hospital mortality linked to aspiration pneumonia. The authors also caution that disease severity was not controlled for, so the referral finding shouldn't be read as proof that referral adds no benefit. (pubmed.ncbi.nlm.nih.gov)

What to watch: Prospective studies that control for case severity will be important to confirm whether prednisolone and clopidogrel truly improve survival, and to clarify which Pug patients still benefit most from referral. (pubmed.ncbi.nlm.nih.gov)